India to New Zealand: Allopurinol Export Trade Route
India has recorded 35 verified shipments of Allopurinol exported to New Zealand, representing a combined trade value of $132.6M USD. This corridor is served by 3 active Indian exporters, with an average shipment value of $3.8M USD. The leading Indian exporter is IPCA LABORATORIES LIMITED, which accounts for 99% of total export value with 26 shipments worth $131.4M USD. On the buying side, NA is the largest importer in New Zealand with $132.6M USD in purchases. The top 3 suppliers — IPCA LABORATORIES LIMITED, INDOCO REMEDIES LIMITED , INDOCO REMEDIES LIMITED — together control 100% of total trade value on this route. All data sourced from Indian Customs (DGFT) shipping bill records. Values reported in FOB USD.
Route Intelligence Overview
The India to New Zealand Allopurinol corridor is one of India's established pharmaceutical export routes, with 35 shipments documented worth a combined $132.6M USD. The route is dominated by IPCA LABORATORIES LIMITED, which alone accounts for roughly 99% of all export value, reflecting the consolidated nature of India's allopurinol manufacturing sector.
Across 3 active suppliers, the average shipment value stands at $3.8M USD — a figure that reflects both bulk commercial orders from large pharmaceutical companies and smaller specialty shipments. Sea freight dominates at 70% of all shipments, consistent with allopurinol's non-urgent bulk-order profile.
Shipment activity peaks during April–June, with an average transit time of 27 days port-to-port. The route has recorded an annual growth rate of 12.6%, placing it at rank #1 among India's top allopurinol export destinations globally.
On the import side, key buyers of Indian allopurinol in New Zealand include NA. NA is the single largest importer with 35 shipments valued at $132.6M USD.
